Celeris Therapeutics develops AI-designed proximity-inducing compounds, including PROTACs and molecular glues, to selectively degrade disease-associated proteins
Celeris Therapeutics develops AI-designed proximity-inducing compounds, including PROTACs and molecular glues, to selectively degrade disease-associated proteins. Its CelerisTx One closed-loop platform combines machine-learning-based interaction prediction, generative molecular design, compound optimization, and laboratory automation. The company is advancing drug candidates for CNS and oncology and collaborates with pharmaceutical and biotech companies on therapeutic development.